Zelira Therapeutics (ASX:ZLD) has completed another medicinal cannabis trial and passed with flying colours.

This time it was a Phase 1 dose escalation study assessing the safety of its cannabis formulation in chronic pain patients using opioids as a treatment.

The study met its primary end points in being well tolerated and having no serious adverse effects.

Pot stock Zelira Therapeutics successfully passes another Phase I clinical trial